These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 36332928)

  • 1. Improving access to medicines: lessons from 10 years of drug reforms in China, 2009-2020.
    Mao W; Jiang H; Mossialos E; Chen W
    BMJ Glob Health; 2022 Nov; 7(11):. PubMed ID: 36332928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The challenge of healthcare big data to China's commercial health insurance industry: evaluation and recommendations.
    Wu J; Qiao J; Nicholas S; Liu Y; Maitland E
    BMC Health Serv Res; 2022 Sep; 22(1):1189. PubMed ID: 36138390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Policy experimentation and innovation as a response to complexity in China's management of health reforms.
    Husain L
    Global Health; 2017 Aug; 13(1):54. PubMed ID: 28774319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of promoting access to medicines in China - problems and recommendations.
    Sun J; Hu CJ; Stuntz M; Hogerzeil H; Liu Y
    BMC Health Serv Res; 2018 Feb; 18(1):125. PubMed ID: 29458428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. China's Health Reform Update.
    Liu GG; Vortherms SA; Hong X
    Annu Rev Public Health; 2017 Mar; 38():431-448. PubMed ID: 28125384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceuticals--strategic considerations in health reforms in Pakistan.
    Nishtar S
    J Pak Med Assoc; 2006 Dec; 56(12 Suppl 4):S100-11. PubMed ID: 17595837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does economic incentive matter for rational use of medicine? China's experience from the essential medicines program.
    Chen M; Wang L; Chen W; Zhang L; Jiang H; Mao W
    Pharmacoeconomics; 2014 Mar; 32(3):245-55. PubMed ID: 23813440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An analysis of China's national essential medicines policy.
    Guan X; Liang H; Xue Y; Shi L
    J Public Health Policy; 2011 Aug; 32(3):305-19. PubMed ID: 21614030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts.
    Hu J; Mossialos E
    Health Policy; 2016 May; 120(5):519-34. PubMed ID: 27080345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving access to medicines by popularising generics: a study of 'India's People's Medicine' scheme in two districts of Maharashtra.
    Lavtepatil S; Ghosh S
    BMC Health Serv Res; 2022 May; 22(1):643. PubMed ID: 35562697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How China's new health reform influences village doctors' income structure: evidence from a qualitative study in six counties in China.
    Zhang S; Zhang W; Zhou H; Xu H; Qu Z; Guo M; Wang F; Zhong Y; Gu L; Liang X; Sa Z; Wang X; Tian D
    Hum Resour Health; 2015 May; 13():26. PubMed ID: 25940189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of the reference pricing policy in China on drug procurement and cost.
    Jiang B; Zhou RJ; Feng XL
    Health Policy Plan; 2022 Jan; 37(1):73-99. PubMed ID: 34379765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achievement of equity and universal access in China's health service: a commentary on the historical reform perspective from the UK National Health Service.
    Wan YC; Wan YI
    Glob Public Health; 2010; 5(1):15-27. PubMed ID: 19946810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engaging sub-national governments in addressing health equities: challenges and opportunities in China's health system reform.
    Brixi H; Mu Y; Targa B; Hipgrave D
    Health Policy Plan; 2013 Dec; 28(8):809-24. PubMed ID: 23221008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards universal health coverage: lessons from 10 years of healthcare reform in China.
    Tao W; Zeng Z; Dang H; Lu B; Chuong L; Yue D; Wen J; Zhao R; Li W; Kominski GF
    BMJ Glob Health; 2020; 5(3):e002086. PubMed ID: 32257400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Helping the decision maker effectively promote various experts' views into various optimal solutions to China's institutional problem of health care provider selection through the organization of a pilot health care provider research system.
    Tang L
    Health Res Policy Syst; 2013 Apr; 11():11. PubMed ID: 23557082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China.
    Fang Y; Wagner AK; Yang S; Jiang M; Zhang F; Ross-Degnan D
    Lancet Glob Health; 2013 Oct; 1(4):e227-37. PubMed ID: 25104348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intended and unintended consequences of China's zero markup drug policy.
    Yi H; Miller G; Zhang L; Li S; Rozelle S
    Health Aff (Millwood); 2015 Aug; 34(8):1391-8. PubMed ID: 26240254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Essential medicine policy in China: pros and cons.
    Hu S
    J Med Econ; 2013; 16(2):289-94. PubMed ID: 23215958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanding public health in China: an empirical analysis of healthcare inputs and outputs.
    Deng F; Lv JH; Wang HL; Gao JM; Zhou ZL
    Public Health; 2017 Jan; 142():73-84. PubMed ID: 28057203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.